Trial Profile

Cerebral Microbleeds as Predictor of Future Intra-Cerebral Hemorrhage During NOACs or Warfarin Therapy in NVAF Patients With Acute Ischemic Stroke (CMB-NOW)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edoxaban (Primary) ; Apixaban; Dabigatran etexilate; Rivaroxaban; Warfarin
Indications Stroke
Focus Therapeutic Use
Acronyms CMB-NOW

Most Recent Events

18 Oct 2016 Status changed from recruiting to active, no longer recruiting.
08 Mar 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
08 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com